The phase 2 trial showed a 42% response rate with lete-cel in synovial sarcoma and MRCLS, with manageable adverse events.

The SU2C-SARC032 study demonstrated that pembrolizumab combined with radiotherapy and surgery was well tolerated, with ...

Dalpiciclib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Well Differentiated Liposarcoma.

Years ago, a family member was diagnosed with an extremely rare cancer: Liposarcoma of the Spermatic Cord. Fewer than... The ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

In recent years, an increasing number of studies have utilized molecular biology techniques to reveal important molecular heterogeneity among different subtypes of liposarcoma. Each subtype exhibits ...